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Abstract
Hepatitis B virus encoded X antigen (HBxAg) may
contribute to the development of hepatocellular carcin-
oma (HCC) by up- or downregulating the expression of
cellular genes that promote cell growth and survival. To
test this hypothesis, HBxAg-positive and -negative
HepG2 cells were constructed, and the patterns of
cellular gene expression compared by polymerase
chain reaction select cDNA subtraction. The full - length
clone of one of these upregulated genes (URG), URG4,
encoded a protein of about 104 kDa. URG4 was strongly
expressed in hepatitis B-infected liver and in HCC cells,
where it costained with HBxAg, and was weakly ex-
pressed in uninfected liver, suggesting URG4 was an
effector of HBxAg in vivo. Overexpression of URG4 in
HepG2 cells promoted hepatocellular growth and sur-
vival in tissue culture and in soft agar, and accelerated
tumor development in nude mice. Hence, URG4 may be
a natural effector of HBxAg that contributes importantly
to multistep hepatocarcinogenesis.
Neoplasia (2002) 4, 355–368 doi:10.1038/sj.neo.7900241
Keywords: hepatitis B virus, hepatitis Bx antigen, hepatocellular carcinoma, oncogene,
pathogenesis.
Introduction
Hepatitis B virus (HBV) is a major etiologic agent associated
with chronic liver diseases, such as hepatitis, cirrhosis, and
hepatocellular carcinoma (HCC) [1,2]. HCC is among the
most common tumor types worldwide, with more than
370,000 cases diagnosed annually, and a survival rate of
<3% over 5 years [2,3]. The relative risk of HBV carriers
developing HCC is in excess of 100, suggesting that the
relationship between HBV and HCC is one of tightest
between a virus and a human cancer [2,4 ].
The molecular mechanisms underlying this high risk for
tumor development are incompletely understood, although
the chronic carrier state and the progression of chronic liver
disease are major risk factors [1–5]. HBV also encodes a
protein known as hepatitis Bx antigen (HBxAg) that appears
to participate in the development of HCC [6,7]. For example,
the X gene of HBV is commonly integrated into host DNA at
many, apparently random sites [8]. Many of these integration
events result in the generation of X region mRNA [9,10] and
HBxAg [11–14] in infected liver and tumor. HBxAg also
directly correlates with the severity of liver disease [15]. In
some strains of X transgenic mice with sustained high levels
of HBxAg, HCC develops [16,17]. X region DNA from the
virus genome and from HCC nodules have been shown to
transform a liver cell line [18,19]. These independent lines of
evidence suggest that HBxAg contributes importantly to
hepatocarcinogenesis.
HBxAg is a trans -activating protein [20], and it has been
proposed that the effects of HBxAg on the transcription of
cellular genes underlies the mechanism whereby HBV
contributes to the high risk of HCC [6,7]. Interestingly, HBxAg
trans -activation appears to be carried out through the
stimulation of multiple cytoplasmic signal transduction path-
ways, such as those involving ras [21], nuclear factor kappaB
(NF-B) [22], activating protein-1 (AP-1) [23], and janus
kinase (JAK)/signal transducer and activator of transcription
(STAT) [24]. In the nucleus, HBxAg trans -activation appears
to involve the binding of HBxAg to a variety of transcription
factors, such as a subunit of RNA polymerase II [25], TATA
bindingprotein [26], activating transcription factor -2 [27], and
other components of the basal transcriptional machinery
[28,29]. HBxAg also binds to an ultraviolet - induced DNA
binding protein involved in DNA repair [30], and disrupts p53/
excision-repair cross-complementing type 3 protein com-
plexes [31], which may disrupt transcription coupled repair,
suggesting that HBxAg may promote the accumulation of
mutations. In addition, HBxAg binds to and inactivates the
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negative growth regulators p53 [31,32] and p55sen [33], as
well as decrease the expression of the cyclin -dependent
kinase inhibitor p21WAF1 /CIP1 /SDI1 [34] and the translation
initiation factor sui1 [35], both of which also negatively
regulate cell growth. Hence, there are multiple pathways
whereby HBxAgmay alter cellular gene expression. It is likely
that these alterations contribute importantly to hepatocar-
cinogenesis, because HBxAg regulates apoptosis [36-38],
mediates resistance to anti–Fas killing [39], stimulates cell
cycle [40], andpromotessurvival in serum-freemedium [39].
With few exceptions, the natural effectors of HBxAg that
promote tumor development have not been identified or well
characterized. For example, HBxAg appears to upregulate
the expression of insulin- like growth factor 2 ( IGF-2) and
the IGF-1 receptor in HCC [41,42]. Given that the IGF-1
receptor binds to both IGF-1 and -2, it is possible that
HBxAg may set up an autocrine loop that enhances cell
growth. HBxAg also reportedly trans -activates c- jun,
alphafetoprotein, and the pancreatic secretory trypsin
inhibitor in reporter gene assays [43,44], but it is not known
whether these events occur in vivo. To systematically
identify natural effectors of HBxAg, experiments were
designed to test the hypothesis that the introduction of
HBxAg into HepG2 cells is associated with the altered
expression of selected cellular proteins. This work identifies
and characterizes one of the HBxAg upregulated genes
(URG), referred to as URG4, which accelerates cell growth
and promotes tumor formation.
Materials and Methods
Cell Lines and Tissue Culture Conditions
The human hepatoblastoma cell line, HepG2 [45] (ATCC,
Manassas, VA), was cultured on type-1 rat tail collagen
(Becton Dickinson, Franklin Lakes, NJ) -coated tissue
culture dishes or plates. Cells were grown in Earle’s modified
Eagle’s medium supplemented with 10% heat- inactivated
fetal calf serum (FCS), 100 M minimal essential medium
non–essential amino acids, 1 mM sodium pyruvate, as well
as standard concentrations of penicillin plus streptomycin.
HepG2.2.2.15 cells (a kind gift from Dr. George Acs,
Mount Sinai School of Medicine), which support HBV
replication [46], and the retrovirus packaging cell line,
PA317 [47], were also grown in the same conditions.
Plasmids
The retroviral plasmid, pSLXCMVneo, was used to clone
the HBV X gene or the bacterial chloramphenicol acetyl-
transferase (CAT) gene sequences, exactly as described
[33,48]. To verify correct cloning, DNA samples were
prepared by using Wizard Plus Minipreps DNA Purification
Systems (Promega, Madison, WI) and then sequenced in
the DNA sequencing facility at the Kimmel Cancer Institute of
Thomas Jefferson University.
pcDNA3 (Invitrogen, SanDiego, CA) was used to clone
full - length upregulated gene, clone 4 (URG4) cDNA under
the control of the immediate early CMV promoter and also
used for the cloning of the HBx open reading frame, as
described [35].
Establishment of HBxAg-Positive and -Negative HepG2
Cells
Recombinant retroviruses encoding HBx ( from pSLX-
CMV–HBx) or CAT (from pSLXCMV–CAT) were prepared
[49], titered, and then used to transduce separate cultures of
HepG2cells,asdescribed [48].Cultureswere thenselected in
G418 for 14 days to maximize the fraction of cells producing
HBxAg or CAT. Standard CAT assays were performed on
HepG2CAT lysates using 14C-chloramphenicol, and acety-
lated forms were separated by thin- layer chromatography
[35,48]. Lysates prepared from 5106 HepG2X cells
were assayed for HBxAg by Western blotting with a mixture
of HBx peptide antibodies using previous published proce-
dures [35,48].
Polymerase Chain Reaction (PCR) Select cDNA
Subtraction, Cloning, Sequencing, and Identification
of a cDNA from a Putative HBxAg Effector
The differences in gene expression, which distinguish
HepG2X from HepG2CAT cells, were determined by using a
commercially available subtraction hybridization approach
( the PCR-select cDNA subtraction kit from Clontech, Palo
Alto, CA) according to the instructions provided by the
manufacturer, with minor modifications [48]. The PCR
fragments corresponding to differentially expressed mRNA
were cloned, sequenced, and compared to existing sequen-
ces in GenBank. One of these differentially expressed PCR
fragments, initially designated as URG4, was chosen for
further characterization.
Cloning and Sequencing the Full -Length URG4 cDNA
The full - length cDNA clone containing the URG4
sequences was obtained by the rapid amplification of 50
and 30 cDNA ends PCR method using the Marathon cDNA
Amplification Kit (Clontech) as described [48]. Briefly, one 30
and one 50 gene specific primers were synthesized. By using
these gene-specific primers together with an adaptor primer,
PCRwas performed with human placental cDNA as template
to get the 30 or 50 cDNA-specific products in separate
amplification reactions. The products were cloned into
pT7Blue(R) T vector (Novagen, Madison, WI) and
sequenced. The appropriate 30 and 50 gene-specific frag-
ments were then digested with NotI and BclI restriction
enzymes and cloned into pcDNA3 (Invitrogen) at the chosen
sites. The integrity of the full - length clone was verified by
DNA sequencing. The full - length sequence was compared
to those for homology to known genes in NCBI–GenBank
using the nucleotide Basic Local Alignment Search Tool.
Preparation and Use of URG4 Antisera
The full - length cDNA from URG4 was used to deduce the
corresponding amino acid sequence using the TRANSLATE
program. Hydrophilic and potentially antigenic peptides were
deduced from the PEPTIDESTRUCTURE and PLOT-
STRUCTURE programs [50] and made by solid phase
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peptide synthesis in the Peptide Synthesis Facility on
campus. Two peptides, which span inclusive residues
460–483 (24 amino acids) and 821–838 (18 amino acids),
were coupled to keyhole limpet hemocyanin carrier and used
to raise antisera in New Zealand rabbits ( two rabbits /
peptide), as described [51]. Antisera were initially charac-
terized by specific enzyme- linked immunosorbent assays.
For Western blotting, each antiserum was used at a dilution
of 1:1000, and blotting was conducted by using a mixture of
antisera from both specificities. Western blots for  -actin
were performed as an internal (sample loading) control
using commercially available antibody (Ab-1; Oncogene
Research Products, Cambridge, MA), as described [35].
Horseradish peroxidase-conjugated goat anti–rabbit Ig
(Accurate, Westbury, NY) and ECL substrate (Amersham,
Arlington Heights, IL) were used for detection.
Immunohistochemical staining was performed on slides
prepared from formalin - fixed, paraffin -embedded tissues
using the Vectastain Elits avidin–biotin-complex Kit accord-
ing to manufacturer’s instructions (Vector laboratories,
Burlingame, CA) with minor modifications [14]. A mixture
of rabbit antibodies raised against URG4 (each at 1:4000
dilution) or HBxAg (used at a dilution of 1:8000) synthetic
peptides were used as primary antibodies. Biotinylated anti–
rabbit Ig was used as secondary antibody, and diaminoben-
zidine was used as substrate for detection. Preimmune
serum or preincubation of primary antibodies with an excess
of the corresponding synthetic peptide(s) (25 g of each
peptide for 1 hour at 378C) served as controls. For HBxAg
staining, uninfected liver was used as an additional control.
Immunohistochemistry was evaluated independently by two
pathologists counting stained and total hepatocytes in five
random fields per slide by light microscopy at a magnification
of 200.
Construction of URG4-Overexpressing HepG2 and Control
Cells
To study the properties of URG4 compared to HBxAg on
the cellular level, separate cultures of 1106 HepG2 cells
were stably transfected with 10 g of pcDNA3, pcDNA3–
URG4, or pcDNA3–HBx using SuperFect transfection
reagent (QIAGEN, Valencia, CA) according to the instruc-
tions provided by the manufacturer. Cells were selected with
G418 (800 g/ml) for 4 weeks. URG4 and HBx mRNA
expression was assayed by Northern blotting, whereas
protein expression was characterized by immunostaining or
Western blotting [35,48].
RNA Isolation and Northern Blot Analysis of URG4
Total RNA was isolated from HepG2X, HepG2CAT,
HepG2.2.15, HepG2–pcDNA3, or HepG2–pcDNA3–
URG4 cells using Tri -Reagent (Molecular Research Center,
Cincinnati, OH). Extracted RNA was precipitated with
isopropanol, and then assessed for integrity of ribosomal
RNA by agarose gel electrophoresis. RNA samples were
then blotted onto nylon membranes (Hybond-N, Amer-
sham). Northern blotting was carried out using the URG4
probe obtained from cDNA subtraction that had been labeled
by random priming (Amersham). Following autoradiographic
exposure, membranes were stripped and rehybridized with a
radiolabeled glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) probe (Clontech). The G3PDH signal served to
normalize the URG4 mRNA levels following gel scanning.
Patient Samples
Paired tumor and nontumor liver tissues used for analysis
were obtained from 23 Chinese and 14 South African pa-
tients chronically infected with HBV who had undergone
surgery for the removal of their tumors. Additional character-
istics of these patients were previously published [35,48].
Analogous pieces of uninfected human liver from five
Chinese individuals, who were seronegative for HBV, were
available to serve as controls. In addition, paired tumor/
nontumor from lung, breast, thyroid, spleen, stomach,
pancreas, kidney, and sigmoid colon were obtained from
patients who had undergone surgery for the removal of their
tumors at Thomas Jefferson University Hospital. Formalin-
fixed, paraffin-embedded tissues were collected from most
patients, used for diagnostic purposes, and were then made
available for these studies. Use of all tissues for this work
was approved by the Institutional Review Board at Thomas
Jefferson University.
In Situ Hybridization ( ISH)
The URG4 cDNA fragment obtained from PCR select
cDNA subtraction was used as a probe for ISH to validate the
RNA subtraction procedure in HepG2X compared to
HepG2CAT cells, and to detect URG4 mRNA in tumor,
infected liver, and uninfected tissues. ISH was carried out
using the Oncor ISH and digoxigenin/biotin detection kits
according to the instructions provided by the manufacturer
(Oncor, Gaithersburg, MD). Criteria used for evaluation
were the same as that outlined above for immunohistochem-
ical staining.
Growth of HepG2–pcDNA3, –pcDNA3–HBx,
or –pcDNA3–URG4 Cells in Complete or
Serum-Free Medium
HepG2 cells stably transfected with pcDNA3, pcDNA3–
HBx, or pcDNA3–URG4 were seeded into six-well plates in
duplicate and grown in complete or serum-free medium. The
number of viable cells was determined at daily intervals after
seeding for up to 5 days by trypan blue staining. Cell viability
was independently determined using the modified tetrazo-
lium salt (MTT) assay, as described by the manufacturer
(Cell Titer 96 Non–Radioactive Cell Proliferation Assay,
Promega). Results represent three independent experi-
ments, each done in duplicate.
Flow Cytometry
To asses the effect of URG4 on cell growth, 1105
HepG2 cells stably transfected with pcDNA3, pcDNA3–HBx,
or pcDNA3–URG4 were seeded into 60-mm plates and
incubated overnight in complete medium. Cells were
synchronized in serum-free medium for 48 hours, then
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Figure 1. Differential expression of URG4 mRNA in HepG2X compared to HepG2CAT cells by ISH and Northern blot analysis. ISH was performed on HepG2X cells
(A ) and HepG2CAT cells (B ) using the cDNA fragment of URG4 obtained from cDNA subtraction as probe (original magnification, 20 ). Northern blot analysis of
RNA extracted from HepG2CAT (panel C, lane 1 ) and HepG2X (panel C, lane 2 ) cells using the URG4 probe, and after stripping the membrane, with the G3PDH
probe. The normalized average ratio of URG4 mRNA in HepG2CAT:HepG2X cells is indicated below the blot. ISH was also performed on fresh frozen sections of
HCC (D ), nontumor liver from a carrier (E ), and uninfected liver (F ). In panel G, the tissue in panel C was hybridized with an irrelevant probe. (H ) Northern blot
analysis of URG4 mRNA from nontumor samples of two patients ( lanes 1 and 2 ), from tumor samples of two patients ( lanes 3 and 4 ), and from two uninfected liver
samples ( lanes 5 and 6 ). The G3PDH controls for lanes 1–6 are in lanes 7–12.
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incubated in 10% FCS containing medium, fixed, stained
with propidium iodine, and analyzed by the Flow Cytometry
Facility at Thomas Jefferson University at 24 and 48 hours
time points.
Growth of URG4-Overexpressing Cells in Soft Agar and in
Nude Mice
HepG2–pcDNA3, HepG2–pcDNA3–HBx, and HepG2–
pcDNA3–URG4 were tested for anchorage- independent
growth in soft agar and for tumor formation in nude mice. For
growth in soft agar, 1104 cells /well were seeded in
triplicate into six-well plates, and allowed to grow for 21
days. The colonies were then counted under code. For
tumorigenicity assays, 1107 viable cells (by trypan blue
exclusion) were injected subcutaneously at a single site in
nude mice. The mice were observed over 6 weeks for tumor
formation. The mice were then sacrificed and the tumors
recovered for further analysis. The use of mice for this work
was reviewed and approved by the Institutional Animal Care
and Use Committee at Thomas Jefferson University.
Statistical Analysis
The relationship between ISH and protein staining results
for URG4, and between URG4 and HBxAg staining, have
been evaluated in 22 tables in a two- tailed analysis. The
results were significant when P<.05. The mean difference in
growth between HepG2 cell stably transfected with pcDNA3,
pcDNA3–HBx, or pcDNA3–URG4 was analyzed using the
Student’s t test. A significant difference was recognized
when P<.05.
Results
PCR Select cDNA Subtraction and Identification of URG4
It has been proposed that HBxAg trans -activating proper-
ties contribute to the altered patterns of host gene expression
that is important for the development of HCC [7]. To test this
hypothesis, HepG2 cells were transduced with recombinant
retroviruses encoding HBxAg or the bacterial CAT gene.
When RNA from these two cultures were compared by PCR
select cDNA subtraction, eight up- and two downregulated
genes were observed. One of these upregulated genes,
URG4, consisted of a cDNA fragment of 1.7 kb in length
that was 99% homologous to an uncharacterized segment in
the short arm of chromosome 7.
Before characterizing this gene product in detail, this
cDNA fragment was used as a probe for ISH and for
Northern blot analysis to verify that the subtractive hybrid-
ization worked. When this probe was used for ISH on
HepG2X cells, the great majority of the cells showed a dark
cytoplasmic brown staining (Figure 1A ). In contrast, ISH on
HepG2CAT cells showed faint or no staining (Figure 1B ).
ISH with an irrelevant probe [pT7Blue(R) T] failed to
hybridize to either HepG2X or HepG2CAT cells (data not
shown). To quantitate the differences in URG4 mRNA levels
in HepG2X compared to HepG2CAT cells, the 1.7-kb URG4
cDNA fragment was used as a probe in Northern blot
analysis. A G3PDH probe, which detected an RNA at about
1.3 kb, was used for normalization. The URG4 probe
detected a single band of about 3.6 kb in size that is
expressed 5.8±0.3 times higher in HepG2X compared to
HepG2CAT cells (Figure 1C ). These combined results verify
that the PCR select cDNA subtraction procedure yielded a
cDNA fragment that was upregulated in HepG2X compared
to HepG2CAT cells.
Expression of URG4 in Tumor, Nontumor, and Uninfected
Liver
If URG4 is an effector of HBxAg that is important for tumor
development, then its expression should be upregulated in
the livers and/or tumors of HBV carriers compared to liver
tissues from uninfected individuals. To test this hypothesis,
ISH was performed in tumor and surrounding nontumor liver,
as well as in tissues from five uninfected individuals. The
URG4 cDNA probe yielded easily detectable signals in tumor
cells (Figure 1D ) from 8 of 14 South African patients (57%)
and from 11 of 23 Chinese patients (48%) (Table 1),
suggesting that URG4 was expressed in HCC. In nontumor
tissue, the URG4 probe also yielded widespread and strong
signals (Figure 1E ) in 13 of 14 South African patients (93%)
and in 21 of 23 Chinese patients (91%) (Table 1).
In contrast, faint ISH signals were observed in three of the
five livers from uninfected individuals (60%) (Figure 1F,
Table 1). ISH of nontumor liver tissue from the same patient
in Figure 1E with an irrelevant probe [pT7Blue(R) T vector ]
yielded no detectable signal (Figure 1G ), underscoring the
specificity of the method. Since the hybridization signals in
nontumor liver tissue from many patients in both populations
appeared to be more intense than the signals observed in the
corresponding tumor cells from the same patients, a more
quantitative measure of these differences was obtained by
Northern blotting. In samples where intact RNA was
obtained, Northern blot analysis showed a single band at
about 3.6 kb in extracts from both tumor and nontumor
tissue, although the levels in nontumor tissue (Figure 1H,
lanes 1 and 2) were up to several fold higher than in
corresponding tumor tissue (Figure 1H, lanes 3 and 4) from
the same patients. This RNA is the same size as that
Table 1. Summary of ISH Results for the URG4 Probe in Tumor /Nontumor
Pairs for HCC Patients from South Africa and China.
South African Patients Uninfected Livers
Case No.: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2 3 4 5
tumor 0 1 0 0 1 2 4 1 1 0 1 0 0 1
nontumor 4 2 2 2 3 4 4 2 2 3 4 0 1 2 1 1 0 1 0
Chinese Patients
Case No.: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
tumor 1 0 1 0 1 1 0 1 0 0 0 1 2 1 0 1 0 0 1 0 0 0 1
nontumor 1 2 1 1 2 1 0 2 1 1 1 2 1 2 2 2 1 0 2 2 3 4 2
ISH staining is estimated as follows: 0: no signal; 1: ISH signal in <10% of
cells; 2: ISH signal in 10–25% of cells; 3: ISH signal in 25–50% of cells; 4:
ISH signal in >50% of cells. T: tumor; NT: nontumor.
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observed in HepG2 cells (Figure 1C ). In contrast, lower
levels of hybridization were observed in uninfected liver
tissues (Figure 1H, lanes 5 and 6), suggesting that the
expression of URG4 is higher in infected compared to
uninfected tissue, and that it is generally higher in nontumor
compared to tumor cells.
Cloning of Full -Length URG4 and Characterization of URG4
Protein Expression
Based on the results of ISH, full - length URG4 cDNA was
obtained by rapid amplification of 50 and 30 cDNA ends, and
the full - length cDNA then cloned into pcDNA3. Sequence
analysis of URG4 cDNA showed a short 50 untranslated
region of 13 bases, followed by an open reading frame of
2766 bases that encodes a polypeptide 922 amino acids long
with a calculated molecular weight of 103,876 Da (Figure 2).
The 30 untranslated region consists of 828 bases, which adds
up to 3.607 kb for the full - length URG4 mRNA. This is
approximately the size of the RNA detected by Northern
blotting in HepG2 cells (Figure 1C ) and in liver (Figure 1H ).
The URG4 polypeptide did not have any identifiable motifs
suggesting function, save the existence of a possible ATP/
GTP binding site motif spanning amino acids 690–697.
Functional analysis failed to show that URG4 bound to or
hydrolyzed any of the nucleoside triphosphates, suggesting
that this putative binding site motif is not active (data not
shown). When the full - length URG4 sequence was ana-
lyzed by the basic local alignment search tool to find
Figure 2. Nucleic acid and protein sequence of full - length URG4. The putative adenosine triphosphate / guanosine triphosphate binding site spans amino acids
690–697 (corresponding to nts 2081–2102 ) and is bold, italicized, and underlined. The synthetic peptides made to raise corresponding antisera are underlined.
Peptide A spans amino acid residues 457–480 (24 amino acids ) ( corresponding to nts 1382–1451 ) and peptide B spans amino acid residues 817–834 (18 amino
acids ) ( corresponding to nts 2462–2513 ).
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homology with known genes, the search again failed to
identify URG4 with any previously published sequence.
To determine the patterns of URG4 protein distribution,
selected synthetic peptides were made (Figure 2) and used
to generate corresponding antibodies in rabbits. Immuno-
histochemical staining was then carried out with formalin -
fixed, paraffin -embedded tissue samples from South African
and Chinese carriers. Among South African patients,
staining was observed with anti -URG4 in tumor tissue from
8 of 14 patients (57%), whereas staining was observed in 11
of 23 tumor samples from Chinese patients (48%) (Table 2).
In surrounding nontumor liver tissue, staining with anti -
URG4 was observed in 13 of 14 South African patients
(93%) and in 21 of 23 Chinese patients (91%) (Table 2).
Staining was exclusively cytoplasmic in tumor and nontumor
liver cells from both sets of patients (Figure 3). When URG4
ISH and immunohistochemical results were compared in
tumor for both groups of patients, a strong positive
correlation was observed (P<.001). Similar results were
obtained when these features were compared in nontumor
liver from both groups (P<.001), suggesting upregulation of
both RNA and protein in the same patients. When staining
was conducted in consecutive sections of tumor from
individual patients, there was clear colocalization of URG4
Figure 2. (continued )
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(Figure 3A ) and HBxAg (Figure 3B ). Preimmune rabbit
serum derived from animals that were subsequently immu-
nized with the URG4 synthetic peptides showed no staining
on consecutive tissue sections (Figure 3C ). Identical results
were obtained with preimmune serum from rabbits that were
later immunized with HBxAg polypeptides (data not shown,
but exactly like Figure 3C ). Analogous results were obtained
when staining was performed in infected nontumor liver
tissue using anti -URG4 (Figure 3D ), anti -HBx (Figure 3E ),
or preimmune serum (Figure 3F ). Statistical analysis
independently confirmed the close association between
URG4 and HBxAg in nontumor liver (P<.005). When
sections from uninfected liver were evaluated, weak staining
was observed in the same three of five samples (Figure 3G )
that also had detectable ISH signals (Tables 1 and 2).
Pretreatment of primary antibodies with an excess of the
corresponding synthetic peptides eliminated staining (data
not shown). These results suggest colocalization of URG4
and HBxAg in HCC and surrounding nontumor liver from
HBV- infected patients, and that the expression of URG4 was
apparently upregulated in infected tissue.
To further explore the tissue distribution of URG4, anti -
URG4 was used to stain samples from pancreas, lung,
breast, thyroid, spleen, stomach, kidney, and sigmoid colon
tissue sections from uninfected patients. Staining was
observed in the cytoplasm of up to 10% of ductal epithelial
cells from the pancreas (data not shown). None of the other
uninfected tissues examined had positive staining. URG4
staining was also observed in the tumor cells from a case of
poorly differentiated pancreatic cancer, but was absent from
tumor samples of the lung (non–small cell lung cancer),
thyroid ( follicular adenoma), breast ( invasive intraductal
cancer), sigmoid colon (moderately differentiated adeno-
carcinoma), and kidney (papillary transition cell carcinoma)
(data not shown). In all cases, the results were based on
staining a single normal or tumor specimen of each tissue
type. These results suggest a restricted tissue and tumor-
type distribution of URG4 expression.
Construction and Growth of HepG2 Cells Stably
Transfected with pcDNA3–HBx, pcDNA–URG4,
or pcDNA3
To functionally characterize URG4, independent cultures
of HepG2 cells were stably transfected with pcDNA3,
pcDNA3–HBx, or pcDNA3–URG4, and each of the cell
lines selected in G418. The levels of URG4 mRNA and
protein were then determined in each of the cell lines by
Northern and Western blotting, respectively. Parallel anal-
yses were done with HepG2.2.15 cells to assess URG4
levels in the context of virus replication. Northern blot
analysis (Figure 4A ) showed a single band of 3.6 kb in
HepG2–pcDNA3 cells ( lane 1), whereas the levels were
2.8±0.3- fold higher in HepG2–pcDNA3–HBx cells ( lane
2), and 5.1±0.7- fold higher in HepG2 cells stably trans-
fected with pcDNA3–URG4 ( lane 3). For comparison, the
levels of URG4 mRNA in HepG2.2.15 cells was 2.3±0.23
higher than in HepG2–pcDNA3 ( lane 4). Interestingly, the
levels of URG4 mRNA correlated with the levels of HBxAg
polypeptide, both of which were roughly two- fold higher in
HepG2 cells transduced with recombinant retrovirus encod-
ing HBxAg compared to HepG2 cells stably transfected with
pcDNA3–HBx, suggesting dose dependence (data not
shown). When Western blotting was conducted with lysates
prepared from the cell lines in panel 4A, a major
immunoreactive band at about 105 kDa was expressed in
HepG2–pcDNA3 cells (Figure 4B, lane 1), at 2.3±0.5- fold
higher levels in HepG2–pcDNA3–HBx cells ( lane 2), and
at 5.5±0.6- fold higher levels in HepG2 cells overexpress-
ing URG4 ( lane 3). 35S–URG4 prepared by in vitro trans-
lation was included for comparison ( lane 4). In HepG2.2.15
cells, URG4 was also detected at 2.4±0.28- fold higher
than control cells ( lane 5). The finding that endogenous
URG4 polypeptide comigrates with the in vitro translation
product, and that its size based on sodium dodecyl sulfate /
polyacrylamide gel electrophoresis is similar to the calcu-
lated value for this protein (103,876 Da), suggests that
this band is full - length URG4. These results also verify
the expression of URG4 at different levels in these cell
lines.
Experiments were then designed to ask whether URG4
overexpression altered cell growth and survival. When these
cell lines were grown in tissue culture medium containing
10% FCS (Figure 4C ) or in serum-free medium (Figure 4D ),
HepG2–pcDNA3–HBx cells grew faster than HepG2–
pcDNA3 cells. Statistical analysis showed a significant
difference in medium containing 10% FCS on days 2
(P=.027), 3 (P=.01), 4 (P=.006), and 5 (P=.002), and in
serum-free medium on days 2 (P=.008), 3 (P=.025), 4
(P=.004), and 5 (P=.002). HepG2 cells that overexpressed
URG4 also significantly stimulated the growth in medium
containing 10% FCS on days 2 (P=.033), 3 (P=.022), 4
(P=.012), and 5 (P=.005) compared to HepG2–pcDNA3
controls. HepG2.2.15 cells, which also had elevated URG4
(Figure 4B ), grew significantly faster than control cells on
days 2–5 ( .02<P<.03), although slower than HepG2–
pcDNA3 and HepG2–pcDNA3–HBx on days 4 and 5
(Figure 4C ). When HepG2–pcDNA3–URG4 cells were
Table 2. Summary of Immunohistochemistry ( IHC ) for the URG4 and HBxAg
in Tumor /Nontumor Pairs for HCC Patients from South Africa and China.
South African Patients Uninfected Livers
Case No.: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2 3 4 5
T: URG4 0 1 0 1 1 0 3 1 1 0 2 0 0 1
HBxAg 0 1 0 2 2 0 3 0 1 0 1 0 0 0
NT: URG4 3 2 2 1 3 2 4 3 1 2 3 0 2 3 1 1 0 1 0
HBxAg 1 2 1 3 3 0 4 1 1 2 2 0 0 1 0 0 0 0 0
Chinese Patients
Case No.: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
T: URG4 2 0 1 0 1 1 0 2 0 0 0 1 1 2 0 1 0 0 1 0 0 0 2
HBxAg 1 0 0 1 0 1 0 2 1 0 1 0 0 1 0 2 0 0 0 0 0 2 2
NT: URG4 2 1 2 2 2 1 0 3 2 1 2 1 1 2 2 3 1 0 2 1 2 4 3
HBxAg 3 1 1 2 1 2 1 3 1 0 2 1 1 1 2 3 2 0 1 2 1 2 2
Staining is estimated as follows: 0: no signal; 1: IHC signal in <10% of cells;
2: IHC signal in 10–25% of cells; 3: IHC signal in 25–50% of cells; 4: IHC
signal in >50% of cells. T: tumor; NT: nontumor.
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Figure 3. Immunohistochemical staining for URG4 and HBxAg. (A ) Anti -URG4 staining of HCC tissue from an HBV carrier. (B ) Anti -HBx staining of a consecutive
section from the same patient as in panel A. (C ) Preimmune rabbit serum used to stain a consecutive section from the same patient as in panel A. (D ) Anti -URG4
staining of nontumor liver tissue from an HBV carrier. (E ) Anti -HBx staining of a consecutive section from the same patient as in panel D. (F ) Preimmune rabbit
serum used to stain a consecutive section from the same patient as in panel D. (G ) Anti -URG4 used to stain an uninfected liver. (H ) Preimmune rabbit serum used
to stain a consecutive section of the same uninfected liver. Original magnification in all panels, 200.
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grown in serum-free medium, significant growth stimulation
was observed at days 4 (P=.003) and 5 (P=.002)
compared to HepG2–pcDNA3 cells (Figure 4D ). URG4
also stimulated growth on days 2 (P=.041) and 3 (P=.046)
compared to control cells, although these increases were
near the limits of statistical significance. These results
suggest that URG4 independently stimulates hepatocellular
growth in the absence of HBxAg. However, URG4 over-
expression did not stimulate the growth of HepG2 cells as
much as HBxAg. Statistical analysis showed the differences
in this comparison to be of borderline significance (Figure
4C). To confirm whether URG4 stimulates cell growth, these
cell lines were analyzed by flow cytometry following
synchronization in serum-free medium. At 24 hours after
the addition of 10% FCS to synchronized cells, 25.8% of
HepG2–pcDNA3 cells were in S phase, whereas 38.5% of
HepG2–pcDNA3–URG4-overexpressing cells were in S
phase, and the percentage for HepG2–pcDNA3–HBx cells
was 45.1% (Figure 5). Again, the difference between control
cells and URG4-overexpressing cells was statistically
significant (P=.006), as was the relationship between
control and HepG2–pcDNA3–HBx cells (P=.002). At 48
hours, there was no difference in the percentage of cells in
each culture that were in S phase, and the values ranged
from 21% to 25% of cells in S phase. A larger percentage of
HepG2.2.15 cells were in S phase compared to HepG2–
pcDNA3 cells, although this was less than that observed for
HepG2–pcDNA3–URG4 cells and HepG2–pcDNA3–HBx
(data not shown). Hence, URG4 stimulates cell growth in
culture and promotes the entry of cells into S phase.
Figure 4. URG4 expression and growth of HepG2–pcDNA3, HepG2–pcDNA3–HBx, and HepG2–pcDNA3–URG4. (A ) Northern blot analysis was carried out on
RNA isolated from HepG2–pcDNA3 ( lane 1 ), HepG2–pcDNA3–HBx ( lane 2 ), HepG2–pcDNA3–URG4 cells ( lane 3 ), and HepG2.2.15 ( lane 4 ). Hybridization
was carried out with URG4 or G3PDH probes. The numbers below the lanes are the relative amounts of URG4mRNA in the Northern blot based on gel scanning and
corrected by comparison with the corresponding G3PDH control shown below each lane. (B ) Western blotting with anti -URG4 was conducted on protein isolated
from HepG2–pcDNA3 ( lane 1 ), HepG2–pcDNA3–HBx ( lane 2 ), HepG2–pcDNA3–URG4 ( lane 3 ), and HepG2.2.15 ( lane 5 ). A pcDNA3–URG4 in vitro
translation sample ( lane 4 ) was used as a positive control. The numbers below the lanes are the relative amounts of URG4 protein in the Western blot on gel
scanning and normalized by comparison with the corresponding  - actin loading control shown below each sample. (C and D) Growth curves for HepG2–pcDNA3
(L ), pcDNA3–HBx (5 ), pcDNA3–URG4 (o ), or HepG2.2.15 (4 ) cells in complete medium containing 10% FCS (C ) or in serum- free medium (D ). The curves
represent the average of three independent experiments, each done in duplicate.
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Growth in Soft Agar and Tumor Formation
The URG4-mediated stimulation of HepG2 growth in
culture prompted the design of additional experiments to test
whether this growth stimulation extended to anchorage
independence and tumor formation. When these cell lines
were seeded into soft agar, HepG2–pcDNA3–HBx cells
yielded an average of 44±8 colonies, whereas HepG2–
pcDNA3 control cells yielded 10±3 colonies after 21 days
(P<.005) (Table 3). In comparison, HepG2–pcDNA3–
URG4 cells yielded 24±4 colonies, which was significantly
higher than control cells (P<.01), but not statistically
different than HBxAg-producing cells (P >.1) (Table 3).
Together, these results suggest that URG4 stimulates
growth in soft agar, although not as strongly as HBxAg.
When these cell lines were individually injected subcuta-
neously into the backs of nude mice, the majority of mice
developed tumors, but the tumors formed by injection of
Figure 5. Flow cytometry of HepG2–pcDNA3 (panels A and B), HepG2–pcDNA3–URG4 (panels C and D), and HepG2–pcDNA3–HBx (panels E and F ) cells at
24 hours ( panels A, C, and E ) and 48 hours ( panels B, D, and F ) after synchronization and addition of 10% FCS. The results shown here illustrate one of the three
independent analyses each done in duplicate.
Table 3. Growth of URG4 -Overexpressing HepG2 Cells in Soft Agar.
Experiment No. of Colonies
HepG2–vector HepG2–URG4 HepG2–HBx
1 7±2 20±3 34±6
2 11±3 24±3 47±8
3 12±4 28±5 50±9
Each experiment was done in triplicate.
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HepG2–pcDNA3–URG4 became palpable by 23±3 days
postinjection compared to control cells, which became
palpable by 43±5 days postinjection (P<.005) (Table 4).
The tumors also grew to an average of twice the size in
mice injected with HepG2–pcDNA3–URG4 compared to
control cells, although these differences did not reach
statistical significance (P >.4) (Table 4). Interestingly,
HepG2–pcDNA3–HBx cells also yielded accelerated tumor
growth, and larger tumor size compared to control cells,
although only tumor onset was statistically significant
(P<.02) (Table 4). These results demonstrate that URG4
promotes tumor cell growth in vivo.
Discussion
The alteration of host gene expression by HBxAg may be
important for the pathogenesis of chronic liver disease and
the development of HCC, by activating several signal
transduction pathways and affecting the activation of
selected transcription factors that regulate proliferation,
differentiation, transformation, and invasive growth [5,7]. In
this work, experiments were designed to test the hypothesis
that introduction of HBxAg into HepG2 cells is associated
with altered patterns of host cell gene expression that
regulate cell growth and survival. This report describes the
isolation and partial characterization of a novel gene, URG4,
which is upregulated in the presence of HBxAg, and may
contribute importantly to the development of HCC by
promoting hepatocellular growth and survival.
Based on PCR select cDNA subtraction of RNA obtained
from HBxAg-positive and -negative cell lines, a cDNA
fragment, designated URG4, appeared to be expressed at
higher levels in HBxAg-positive compared to negative cells.
This was confirmed by ISH using the cells from each of these
lines (Figure 1, A and B ) and quantitated by Northern
blotting (Figures 1C and 4A ) as well as Western blotting
(Figure 4B ). These findings validate the subtraction method-
ology used and show that URG4 is upregulated at the RNA
and protein levels in the presence of HBxAg. To determine
whether URG4 was upregulated in HBV infected compared
to uninfected liver, ISH was performed on fresh frozen
sections from HCC, nontumor liver, and uninfected liver
samples. Strong hybridization signals were detected in
nontumor liver samples from HBV- infected patients with
HCC, at lower levels in the tumor cells from some of the
same patients, and at still lower levels in uninfected liver
tissue (Figure 1, D–G ). Again, these results were confirmed
and quantitated by Northern blot analysis (Figure 1H ), and
suggest that URG4 was differentially expressed at the RNA
level in infected compared to uninfected liver tissue. At the
protein level, immunohistochemical staining was noticeably
stronger among infected tumor and nontumor specimens
compared to uninfected liver (Figure 3) suggesting again
that URG4 expression is upregulated in infected compared
to uninfected liver. The fact that HBxAg staining strongly
correlated with that of URG4 (Figure 3) in many patients
from two geographically disperse populations, not only
suggests that URG4 upregulated expression occurs com-
monly in the liver and tumor of carriers with HCC, but also
that URG4 is likely to be a natural effector of HBxAg in vivo.
This is further strengthened by the observation that URG4
polypeptide was upregulated in HBxAg-positive cells, and in
cells replicating HBV compared to HBxAg-negative control
cells (Figure 4B ).
HBxAg stimulates cell growth and survival in a number of
published reports [5,16-18,40,48], and such a property is
likely to contribute importantly to the development of HCC.
Hence, if URG4 is a natural effector of HBxAg in chronic
infection, it should have at least some of the functions
associated with HBxAg. For example, the finding that HBxAg
stimulates growth in medium containing 10% serum as well
as in serum-free medium, and that URG4 also stimulates
growth and survival under these conditions (Figure 4, C and
D ), is consistent with the hypothesis that URG4 is an effector
of HBxAg that carries out, at least in part, an HBxAg-
associated activity that may contribute to the development of
HCC. The fact that URG4 overexpression only partially
stimulates cell growth and survival under these conditions is
consistent with the probability that other HBxAg effectors,
such as the recently published URG7 [48], may also
contribute importantly to hepatocellular growth and survival.
In this context, it will be important to determine whether the
URG4 stimulation of cell growth and survival is associated
with the constitutive activation of one or more signal
transduction pathways that are known to be activated by
HBxAg and that are associated with the HBxAg-mediated
stimulation of cell growth [7,21,40]. HBx stimulates cell cycle
progression by shortening the emergence of cells from
quiescence (G0) and entry into S phase and also accelerat-
ing transit through checkpoint controls at G0/G1 and G2/M
[40]. The data from flow cytometry with URG4-overexpress-
ing cells (Figure 5) is consistent with this possibility. In
addition, by disturbing the regulation of the checkpoint
controls, HBx ( through URG4?) may contribute to genetic
instability, in which unrepaired transforming mutations would
accumulate during the pathogenesis of HCC [40].
HBxAg is also known to transform cells in vitro [18] and
give rise to HCC in selected strains of X transgenic mice
Table 4. Tumor Formation with Subcutaneous Injection of HepG2 Cells Stably Transfected with pcDNA3 or pcDNA3–URG4 in Nude Mice.
Cell Line No. of Mice No. (% ) of Mice with Tumors Tumor Onset (day )* Average Tumor Size ( cm3 )y
HepG2–pcDNA3 20 15 (75 ) 43 0.94±0.34
pcDNA3–URG4 10 10 (100 ) 23 1.96±0.54
pcDNA–HBx 10 7 (70) 36 1.95±0.51
*The day of onset is the first day when a palpable tumor could be detected.yThe average size of tumor was determined on day 50 after the injection of tumor cells.
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characterized by sustained, high levels of HBxAg expression
[16,17]. To test whether URG4 contributes to hepatocarci-
nogenesis, URG4-overexpressing cells were seeded into
soft agar, and tested for anchorage- independent growth,
which is an important, although not invariable feature of the
transformed cell phenotype. The finding that oncogenes
often stimulate anchorage- independent growth when intro-
duced into cells [52,53], and that URG4 stimulates
anchorage- independent growth in soft agar (Table 3),
suggests that URG4 may be an oncogene operative in
hepatocarcinogenesis. This is further supported by the
finding that URG4 stimulates tumor formation in nude mice
(Table 4).
In summary, HBxAg stimulates the expression of an
oncogene in preneoplastic liver that promotes growth factor -
independent survival, anchorage- independent growth, and
accelerates tumor formation. Given that this upregulation
occurs in many patients from two different parts of the world
further suggests that URG4 is a natural effector of HBxAg
that contributes frequently and importantly to the mechanism
of HBxAg-mediated hepatocellular transformation.
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